
Accendra Health, Inc. (NYSE:ACH) (the &#34;Company&#34;) today announced the expiration and final results of the previously announced offers to exchange (the &#34;Exchange Offers&#34;) any and all of the Company’s

<p xmlns="http://www.w3.org/1999/xhtml">
Accendra Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ACH">ACH</a>) (the "Company") today announced the expiration and final results of the previously announced offers to exchange (the "Exchange Offers") any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the "2029 Notes") and 6.625% Senior Notes due 2030 (the "2030 Notes" and, together with the 2029 Notes, the "Existing Notes").

</p><p xmlns="http://www.w3.org/1999/xhtml">
As of 5:00 P.M., New York City time, on June 23, 2026 (the "Expiration Time"), the Company received from Eligible Holders valid and unwithdrawn tenders and related Consents (as defined below), as reported by Epiq Corporate Restructuring, LLC (the "Exchange Agent" and "Information Agent"), representing approximately $478.3 million and $548.0 million in aggregate principal amount of 2029 Notes and 2030 Notes, respectively, or approximately 99.9% and 99.2% of the aggregate principal amount of 2029 Notes and 2030 Notes outstanding at the launch of the Exchange Offers, respectively.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company’s obligation to accept for exchange Existing Notes validly tendered (and not validly withdrawn) pursuant to the Exchange Offers is subject to the satisfaction or, if permitted, waiver of, certain conditions set forth in the confidential offering memorandum and consent solicitation statement, dated May 22, 2026 (the "Offering Memorandum"). Capitalized terms used herein, but not otherwise defined, have the meanings ascribed to such terms in the Offering Memorandum.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In connection with the Exchange Offers, the Company issued or expects to issue a total of: (i) $213.0 million in aggregate principal amount of First Lien Notes and (ii) $698.1 million in aggregate principal amount of Second Lien Notes, in exchange for the validly tendered and accepted Existing Notes, and issued $326.25 million in aggregate principal amount of First Lien Notes in the New Money Notes Issuance, for a total of $539.25 million First Lien Notes.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The offering of the New Notes has not been registered with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act"), or any state or foreign securities laws. The Exchange Offers were only made to holders of Existing Notes that are (a) reasonably believed to be qualified institutional buyers in reliance on Rule 144A promulgated under the Securities Act or (b) non-U.S. persons, in transactions outside the United States, in reliance on Regulation S under the Securities Act (such holders, the "Eligible Holders").

</p><p xmlns="http://www.w3.org/1999/xhtml">
Epiq Corporate Restructuring, LLC has been appointed as the Exchange Agent and the Information Agent for the Offers and Consent Solicitations. Questions concerning the Offers and the Consent Solicitations may be directed to the Exchange Agent and Information Agent, in accordance with the contact details shown on the back cover of the Offering Memorandum.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Ducera Securities LLC has been engaged to act as our financial advisor for the Offers and Consent Solicitations.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">No Offer or Solicitation</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Offers and Consent Solicitations, or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this press release is not an offer of securities for sale into the United States. The New Notes offered in the Offers have not been registered under the Securities Act or any state securities laws, and unless so registered, New Notes may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="bwuline">About Accendra Health</span></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Accendra Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ACH">ACH</a>) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="bwuline">Cautionary Note Regarding Forward-Looking Statements</span></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding our expectations regarding the Offers and Consent Solicitations, the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. The Company cautions readers of this communication that such "forward-looking statements," wherever they occur in this communication or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the "forward-looking statements."

</p><p xmlns="http://www.w3.org/1999/xhtml">
Factors that could cause the Company’s actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the "Risk Factors" sections of our most recent Annual Report on Form 10-K for the period ended December 31, 2025, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54559237&amp;newsitemid=20260623793524&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=1&amp;md5=9500940d295f3e389ae835881df28a98" shape="rect">www.sec.gov</a>. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Current Report on Form 8-K and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

</p><p xmlns="http://www.w3.org/1999/xhtml">
ACH-CORP

</p><p xmlns="http://www.w3.org/1999/xhtml">
ACH-IR

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260623793524r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260623793524/en/" rel="nofollow">https://www.businesswire.com/news/home/20260623793524/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="bwuline">Investors
<br xmlns="http://www.w3.org/1999/xhtml"></br></span></b>Will Parrish
<br xmlns="http://www.w3.org/1999/xhtml"></br>Vice President, Strategy, Corporate Development, &amp; Investor Relations
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:Investor.Relations@accendra.com" shape="rect">Investor.Relations@accendra.com</a>

</p>

Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations

Accendra Health completes high-uptake debt exchange; refinancing progress observed

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>Accendra Health, Inc. (NYSE:ACH) (the &amp;#34;Company&amp;#34;) today announced the expiration and final results of the previously announced offers to exchange (the &amp;#34;Exchange Offers&amp;#34;) any and all of the Company’s</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Accendra Health announced near-complete tender results for its 2029 and 2030 notes, enabling a refinancing of its debt stack. It plans to issue roughly $539.25 million in First Lien notes (including new money) and $698.1 million in Second Lien notes, with $213.0 million of First Lien exchanged directly. The new notes are not SEC-registered and offered to qualified buyers, signaling a potential improvement in leverage and cost of capital pending terms and covenants.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Accendra Health confirms expiration of note exchanges. Results cover 2029 and 2030 notes.</li><li>Tender uptake: 99.9% (2029) and 99.2% (2030) of notes.</li><li>New money issuance totals $326.25m First Lien; total First Lien debt $539.25m.</li><li>Aggregate exchange includes $213.0m First Lien and $698.1m Second Lien issued.</li><li>New notes are not SEC registered; offered to eligible holders under Rule 144A/Reg S.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Accendra Health, Inc. (ACH)</strong>: Subject of the debt refinancing; potential stock impact tied to terms and leverage changes.</li><li><strong>Epiq Corporate Restructuring, LLC (N/A)</strong>: Appointed as Exchange Agent/Information Agent; plays a key operational role in the exchange.</li><li><strong>Ducera Securities LLC (N/A)</strong>: Financial advisor for the offers and consent solicitations.</li></ul>
  </section>

  <section data-block="category">
    <h3>Corporate Developments</h3>
    <p>Category: Corporate Developments. This debt-refinancing move directly reshapes ACH&#039;s capital structure and cost of capital, a key driver of valuation and risk.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>Very high tender uptake reduces risk of failed exchanges and debt rollover concerns.</li><li>Refinancing could lower interest costs if new rates are favorable.</li><li>Not-registered SEC offering may limit broad market acceptance until terms are clear.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Expiration Time: June 23, 2026 at 5:00 P.M. NYC time.</li><li>Tender results: 99.9% of 2029 notes ($478.3m) and 99.2% of 2030 notes ($548.0m).</li><li>New money: $326.25m First Lien; total First Lien debt equals $539.25m; Second Lien $698.1m.</li><li>Aggregate exchange: $213.0m First Lien and $698.1m Second Lien issued.</li><li>New Notes are not registered; offered to eligible holders under Rule 144A/Reg S.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Near-term upside for ACH if refinanced debt improves cash flow; initial move likely within days as details digest.</p>
  </section>
</section>


<p xmlns="http://www.w3.org/1999/xhtml">
Accendra Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ACH">ACH</a>) (the "Company") today announced the expiration and final results of the previously announced offers to exchange (the "Exchange Offers") any and all of the Company’s outstanding 4.500% Senior Notes due 2029 (the "2029 Notes") and 6.625% Senior Notes due 2030 (the "2030 Notes" and, together with the 2029 Notes, the "Existing Notes").

</p><p xmlns="http://www.w3.org/1999/xhtml">
As of 5:00 P.M., New York City time, on June 23, 2026 (the "Expiration Time"), the Company received from Eligible Holders valid and unwithdrawn tenders and related Consents (as defined below), as reported by Epiq Corporate Restructuring, LLC (the "Exchange Agent" and "Information Agent"), representing approximately $478.3 million and $548.0 million in aggregate principal amount of 2029 Notes and 2030 Notes, respectively, or approximately 99.9% and 99.2% of the aggregate principal amount of 2029 Notes and 2030 Notes outstanding at the launch of the Exchange Offers, respectively.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The Company’s obligation to accept for exchange Existing Notes validly tendered (and not validly withdrawn) pursuant to the Exchange Offers is subject to the satisfaction or, if permitted, waiver of, certain conditions set forth in the confidential offering memorandum and consent solicitation statement, dated May 22, 2026 (the "Offering Memorandum"). Capitalized terms used herein, but not otherwise defined, have the meanings ascribed to such terms in the Offering Memorandum.

</p><p xmlns="http://www.w3.org/1999/xhtml">
In connection with the Exchange Offers, the Company issued or expects to issue a total of: (i) $213.0 million in aggregate principal amount of First Lien Notes and (ii) $698.1 million in aggregate principal amount of Second Lien Notes, in exchange for the validly tendered and accepted Existing Notes, and issued $326.25 million in aggregate principal amount of First Lien Notes in the New Money Notes Issuance, for a total of $539.25 million First Lien Notes.

</p><p xmlns="http://www.w3.org/1999/xhtml">
The offering of the New Notes has not been registered with the Securities and Exchange Commission (the "SEC") under the Securities Act of 1933, as amended (the "Securities Act"), or any state or foreign securities laws. The Exchange Offers were only made to holders of Existing Notes that are (a) reasonably believed to be qualified institutional buyers in reliance on Rule 144A promulgated under the Securities Act or (b) non-U.S. persons, in transactions outside the United States, in reliance on Regulation S under the Securities Act (such holders, the "Eligible Holders").

</p><p xmlns="http://www.w3.org/1999/xhtml">
Epiq Corporate Restructuring, LLC has been appointed as the Exchange Agent and the Information Agent for the Offers and Consent Solicitations. Questions concerning the Offers and the Consent Solicitations may be directed to the Exchange Agent and Information Agent, in accordance with the contact details shown on the back cover of the Offering Memorandum.

</p><p xmlns="http://www.w3.org/1999/xhtml">
Ducera Securities LLC has been engaged to act as our financial advisor for the Offers and Consent Solicitations.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml">No Offer or Solicitation</b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release is not intended to and does not constitute an offer to sell or the solicitation of an offer to subscribe for or buy or an invitation to purchase or subscribe for any securities or the solicitation of any vote, consent or approval in any jurisdiction in connection with the Offers and Consent Solicitations, or otherwise, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in contravention of applicable law. In particular, this press release is not an offer of securities for sale into the United States. The New Notes offered in the Offers have not been registered under the Securities Act or any state securities laws, and unless so registered, New Notes may not be offered or sold in the United States or to any U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable state securities laws.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="bwuline">About Accendra Health</span></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
Accendra Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/quote/ACH">ACH</a>) is a leading nationwide provider of products, technology and services that support health beyond the hospital for millions of people each year. We connect patients, providers, and insurers, delivering innovative solutions that help promote better health outcomes and improve quality of life for people living with chronic, complex health conditions. Backed by the industry-leading expertise of our Apria and Byram brands, Accendra Health is reimagining the future of home-based care.

</p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="bwuline">Cautionary Note Regarding Forward-Looking Statements</span></b>

</p><p xmlns="http://www.w3.org/1999/xhtml">
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, statements regarding our expectations regarding the Offers and Consent Solicitations, the future performance and financial results of the Company’s business and other non-historical statements. Some of these statements can be identified by terms and phrases such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should," "could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. The Company cautions readers of this communication that such "forward-looking statements," wherever they occur in this communication or in other statements attributable to the Company, are necessarily estimates reflecting the judgment of the Company’s senior management and involve a number of risks and uncertainties that could cause actual results to differ materially from those suggested by the "forward-looking statements."

</p><p xmlns="http://www.w3.org/1999/xhtml">
Factors that could cause the Company’s actual outcomes or results to differ materially from those described in the forward-looking statements can be found in the "Risk Factors" sections of our most recent Annual Report on Form 10-K for the period ended December 31, 2025, as such factors may be further updated from time to time in the Company’s other filings with the SEC. These reports are or will be accessible on the SEC’s website at <a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=54559237&amp;newsitemid=20260623793524&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=1&amp;md5=9500940d295f3e389ae835881df28a98" shape="rect">www.sec.gov</a>. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this Current Report on Form 8-K and in the Company’s filings with the SEC. The Company undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

</p><p xmlns="http://www.w3.org/1999/xhtml">
ACH-CORP

</p><p xmlns="http://www.w3.org/1999/xhtml">
ACH-IR

</p><p xmlns="http://www.w3.org/1999/xhtml"><img xmlns="http://www.w3.org/1999/xhtml" alt="" src="https://cts.businesswire.com/ct/CT?id=bwnews&amp;sty=20260623793524r1&amp;sid=benz2&amp;distro=nx&amp;lang=en" style="width:0;height:0"></img><span xmlns="http://www.w3.org/1999/xhtml" class="bwct31415"></span></p><p xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink"><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-phrase">View source version on businesswire.com: </span><span xmlns="http://www.w3.org/1999/xhtml" id="mmgallerylink-link"><a xmlns="http://www.w3.org/1999/xhtml" href="https://www.businesswire.com/news/home/20260623793524/en/" rel="nofollow">https://www.businesswire.com/news/home/20260623793524/en/</a></span></p><p xmlns="http://www.w3.org/1999/xhtml">
<b xmlns="http://www.w3.org/1999/xhtml"><span xmlns="http://www.w3.org/1999/xhtml" class="bwuline">Investors
<br xmlns="http://www.w3.org/1999/xhtml"></br></span></b>Will Parrish
<br xmlns="http://www.w3.org/1999/xhtml"></br>Vice President, Strategy, Corporate Development, &amp; Investor Relations
<br xmlns="http://www.w3.org/1999/xhtml"></br><a xmlns="http://www.w3.org/1999/xhtml" rel="nofollow" href="mailto:Investor.Relations@accendra.com" shape="rect">Investor.Relations@accendra.com</a>

</p>

Accendra Health announced near-complete tender results for its 2029 and 2030 notes, enabling a refinancing of its debt stack. It plans to issue roughly $539.25 million in First Lien notes (including new money) and $698.1 million in Second Lien notes, with $213.0 million of First Lien exchanged directly. The new notes are not SEC-registered and offered to qualified buyers, signaling a potential improvement in leverage and cost of capital pending terms and covenants.

Accendra Health Announces Expiration and Final Results of Offers and Consent Solicitations

AI Summary

Sentiment Rationale

Trading Thesis

Market-Moving

Key Facts

Companies Mentioned

Corporate Developments

Related News